Loading Now

We must stay vigilant on false patent extensions and the non-clinical use of weight-loss drugs

We must stay vigilant on false patent extensions and the non-clinical use of weight-loss drugs

We must stay vigilant on false patent extensions and the non-clinical use of weight-loss drugs


Mounjaro, Eli Lilly’s brand of another weight-loss drug called tirzepatide, was launched this March. In just over half a year, it had toppled GlaxoSmithKline’s antibiotic Augmentin as India’s largest selling medicine by value, with sales reported at 100 crore in October. This reveals huge demand for drugs that promise to help people knock off weight.

Post Comment